Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2026)
Amneal Pharmaceuticals has reported Common Equity over the past 9 years, most recently at -$71.3 million for Q4 2025.
- For Q4 2025, Common Equity rose 34.72% year-over-year to -$71.3 million; the TTM value through Dec 2025 reached -$71.3 million, up 34.72%, while the annual FY2025 figure was -$71.3 million, 34.72% up from the prior year.
- Common Equity for Q4 2025 was -$71.3 million at Amneal Pharmaceuticals, up from -$110.0 million in the prior quarter.
- Over five years, Common Equity peaked at $407.4 million in Q1 2022 and troughed at -$132.0 million in Q1 2025.
- A 5-year average of $108.8 million and a median of $142.7 million in 2023 define the central range for Common Equity.
- Biggest five-year swings in Common Equity: crashed 646.03% in 2024 and later soared 34.72% in 2025.
- Year by year, Common Equity stood at $367.0 million in 2021, then plummeted by 49.87% to $184.0 million in 2022, then crashed by 89.12% to $20.0 million in 2023, then crashed by 646.03% to -$109.3 million in 2024, then soared by 34.72% to -$71.3 million in 2025.
- Business Quant data shows Common Equity for AMRX at -$71.3 million in Q4 2025, -$110.0 million in Q3 2025, and -$112.5 million in Q2 2025.